O
Olga Shestakovska
Researcher at Population Health Research Institute
Publications - 35
Citations - 3536
Olga Shestakovska is an academic researcher from Population Health Research Institute. The author has contributed to research in topics: Aspirin & Rivaroxaban. The author has an hindex of 20, co-authored 33 publications receiving 2694 citations. Previous affiliations of Olga Shestakovska include McMaster University & Hamilton Health Sciences.
Papers
More filters
Journal ArticleDOI
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom,Stuart J. Connolly,Jackie Bosch,Gilles R. Dagenais,Robert G. Hart,Olga Shestakovska,Rafael Diaz,Marco Alings,Eva Lonn,Sonia S. Anand,Petr Widimsky,Masatsugu Hori,Alvaro Avezum,Leopoldo S. Piegas,Kelley R. Branch,Jeffrey L. Probstfield,Deepak L. Bhatt,Jun Zhu,Yan Liang,Aldo P. Maggioni,Patricio Lopez-Jaramillo,Martin O'Donnell,Ajay K. Kakkar,Keith A.A. Fox,Alexander Parkhomenko,Georg Ertl,Stefan Störk,Matyas Keltai,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Peter Verhamme,Dragos Vinereanu,Jae-Hyung Kim,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,P. Gabriel Steg,Kaj Metsärinne,Nancy Cook Bruns,Frank Misselwitz,Edmond Chen,Darryl P. Leong,Salim Yusuf +48 more
TL;DR: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Journal ArticleDOI
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
Thomas Vanassche,Mandy N. Lauw,John W. Eikelboom,Jeff S. Healey,Robert G. Hart,Marco Alings,Alvaro Avezum,Rafael Diaz,Stefan H. Hohnloser,Basil S. Lewis,Olga Shestakovska,Jia Wang,Stuart J. Connolly +12 more
TL;DR: In a large population of non-anticoagulated AF patients, pattern of AF was a strong independent predictor of stroke risk and may be helpful to assess the risk/benefit for anticoagulant therapy, especially in lower risk patients.
Journal ArticleDOI
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Paul Moayyedi,John W. Eikelboom,Jackie Bosch,Stuart J. Connolly,Leanne Dyal,Olga Shestakovska,Darryl P. Leong,Sonia S. Anand,Stefan Störk,Kelley R. Branch,Deepak L. Bhatt,Peter Verhamme,Martin O'Donnell,Aldo P. Maggioni,Eva Lonn,Leopoldo S. Piegas,Georg Ertl,Matyas Keltai,Nancy Cook Bruns,Eva Muehlhofer,Gilles R. Dagenais,Jae-Hyung Kim,Masatsugu Hori,P. Gabriel Steg,Robert G. Hart,Rafael Diaz,Marco Alings,Petr Widimsky,Alvaro Avezum,Jeffrey L. Probstfield,Jun Zhu,Yan Liang,Patricio Lopez-Jaramillo,Ajay K. Kakkar,Alexander Parkhomenko,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Tomek J. Guzik,Dragos Vinereanu,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,Kaj Metsärinne,Keith A.A. Fox,Salim Yusuf +50 more
TL;DR: In a large placebo-controlled randomized trial, it is found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections.
Journal ArticleDOI
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy
Michiel Coppens,John W. Eikelboom,Robert G. Hart,Salim Yusuf,Gregory Y.H. Lip,Paul Dorian,Olga Shestakovska,Stuart J. Connolly +7 more
TL;DR: The CHA(2)DS(2)-VASc score reclassifies 26% of patients with a CHADS( 2) score of 1 to a low annual risk of SSE of 1%, which seems low enough to consider withholding anticoagulant treatment.
Journal ArticleDOI
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
Hans-Christoph Diener,John W. Eikelboom,Stuart J. Connolly,Campbell D. Joyner,Robert G. Hart,Gregory Y.H. Lip,Martin O'Donnell,Stefan H. Hohnloser,Graeme J. Hankey,Olga Shestakovska,Salim Yusuf +10 more
TL;DR: In patients with atrial fibrillation, apixaban is similarly effective whether or not patients have had a previous stroke or TIA, and the absolute benefits might be greater in these patients.